IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab. However, whether quantifying T cell-inflamed microenvironment is a useful pan-tumor determinant of PD-1-directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell-inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell-inflamed GEP contained IFN-γ-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell-inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Defects associated with this pathway and its downstream effectors have shown both negative and positive correlations with response to ICB, suggesting a dual role for this pathway in tumor immunity (Ayers et al., 2017; Gao et al., 2016).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several gene signatures capturing the inflamed components of the TME have been associated with a favourable response to ICIs69,72,78–81, but none has been clinically validated thus far.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Interferon (IFN) signaling through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway plays a prominent role in tumor immunity.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“In the clinic, a strong IFN-γ signature has been identified as a useful predictor and indicator of response in anti-PD-1-treated patients across various cancer indications (75,92,93).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [93]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“org Volume 127 Number 8 August 2017 Introduction Cancer cells have the ability to adapt to and avoid host immune checkpoints and surveillance as a means to promote their continued survival (1, 2).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“These data extend the observations of previous reports showing that CD8+ T lymphocytes and T cell active chemokines and T cell counterinhibitory molecules such as PD-1/PD-L1 and IDO1 are coregulated within tumors (4, 15, 21, 22) and confirm that response to anti–PD-1 blockade occurs primarily in patients with such a p…”
ResultSelf-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“Newer genomic technologies can be used to evaluate complexities of tumor and Recently, increased PD-L1 expression on the surface of tumor cells has been identified as an important determinant of response to immune therapies targeting the PD-1 axis (16).”
BackgroundSelf-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 2×
“Likewise, these data provide a much higher level of statistical validation across multiple tumor types than has previously been reported for single genes associated with the IFN-γ signaling pathway and response to PD-1 blockade (17), indicating that integrated multigene signatures might represent more robust predictiv…”
Background
Cited by
Items 901–1,000 of 1,011
Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution
Thol, K., Pawlik, P., & McGranahan, N. (2022) · Genome Medicine · doi:10.1186/s13073-022-01138-3 · Cited by 48
Liu, Z., Liu, L., Jiao, D., Guo, C., Wang, L., Li, Z., Sun, Z., Zhao, Y., & Han, X. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.669694 · Cited by 56
McCaw, T. R., Li, M., Starenki, D., Liu, M., Cooper, S. J., Arend, R. C., Forero, A., Buchsbaum, D. J., & Randall, T. D. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02430-9 · Cited by 50
Nederlof, I., Bortoli, D. D., Barèche, Y., Nguyen, B., de Maaker, M., Hooijer, G. K. J., Buisseret, L., Kok, M., Smid, M., den Eynden, G. G. G. M. V., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1239-4 · Cited by 89
Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer
Tsukagoshi, M., Yokobori, T., Yajima, T., Maeno, T., Shimizu, K., Mogi, A., Araki, K., Harimoto, N., Shirabe, K., & Kaira, K. (2020) · Medicine · doi:10.1097/md.0000000000019059 · Cited by 50
“Furthermore, an interferon-g gene signature is correlated with the response to anti-PD-1 therapy.([21]) For these reasons, the presence of tumor-reactive T cell infiltration is important for a response to anti-PD-1 therapy.”
BackgroundNeuwelt, A. J., Kimball, A. K., Johnson, A. M., Arnold, B. W., Bullock, B., Kaspar, R. E., Kleczko, E. K., Kwak, J., Wu, M., Heasley, L. E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000441 · Cited by 50
Song, L., Bretz, A. C., Gravemeyer, J., Spassova, I., Muminova, S., Gambichler, T., Sriram, A., Ferrone, S., & Becker, J. C. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.08.023 · Cited by 46
M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
Zhao, R., Wan, Q., Wang, Y., Wu, Y., Xiao, S., Li, Q., Shen, X., Zhuang, W., Zhou, Y., Xia, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1862520 · Cited by 52
Wu, X., Su, D., Mei, Y., Xu, M., Zhang, H., Wang, Z., Li, L., Peng, L., Jiang, J., Yang, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02896-6 · Cited by 54
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
Ross‐Macdonald, P., Walsh, A. M., Chasalow, S. D., Ammar, R., Papillon‐Cavanagh, S., Szabó, P. M., Choueiri, T. K., Sznol, M., & Wind‐Rotolo, M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001506 · Cited by 52
What Are the Biomarkers for Immunotherapy in SCLC?
Longo, V., Catino, A., Montrone, M., Pizzutilo, P., Annese, T., Pesola, F., Marech, I., Cassiano, S., Ribatti, D., & Galetta, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011123 · Cited by 49
Nastoupil, L. J., Chin, C. K., Westin, J. R., Fowler, N. H., Samaniego, F., Cheng, X., Ma, M. C. J., Wang, Z., Chu, F., Dsouza, L., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006240 · Cited by 50
Xiong, H., Xi, Y., Yuan, Z., Wang, B., Hu, S., Fang, C., Cai, Y., Fu, X., & Li, L. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2044103 · Cited by 50
Kim, C. G., Koh, J.-Y., Shin, S.-J., Shin, J.-H., Hong, M., Chung, H. C., Rha, S. Y., Kim, H. S., Lee, C.-K., Lee, J. H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101251 · Cited by 45
Gut microbial structural variation associates with immune checkpoint inhibitor response
Liu, R., Zou, Y., Wang, W.-Q., Chen, J.-H., Zhang, L., Feng, J., Yin, J.-Y., Mao, X.-Y., Li, Q., Luo, Z.-Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42997-7 · Cited by 45
Waks, A. G., Keenan, T. E., Li, T., Tayob, N., Wulf, G. M., Richardson, E. T., Attaya, V., Anderson, L., Mittendorf, E. A., Overmoyer, B. A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005119 · Cited by 50
IFN-γ and TGF-β, Crucial Players in Immune Responses: A Tribute to Howard Young
Gauthier, T., & Chen, W. (2022) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2022.0132 · Cited by 51
Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer
Wu, W., Wang, X., Le, W., Lu, C., Li, H., Zhu, Y., Chen, X., An, W., Xu, C., Wu, Q., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001297 · Cited by 50
Padilla, C. M., Valenzi, E., Tabib, T., Nazari, B., Sembrat, J., Rojas, M. M., Fuschiotti, P., & Lafyatis, R. (2023) · Rheumatology · doi:10.1093/rheumatology/kead273 · Cited by 49
Anichini, A., Tassi, E., Grazia, G., & Mortarini, R. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2147-7 · Cited by 47
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment
Clarke, J. M., George, D. J., Lisi, S., & Salama, A. K. S. (2018) · Targeted Oncology · doi:10.1007/s11523-017-0549-7 · Cited by 46
Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies
Hammerl, D., Rieder, D., Martens, J. W. M., Trajanoski, Z., & Debets, R. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.09.004 · Cited by 51
Kossenkov, A. V., Qureshi, R., Dawany, N. B., Wickramasinghe, J. M., Liu, Q., Majumdar, R. S., Chang, C., Widura, S., Kumar, T., Horng, W.-H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2032 · Cited by 49
Human Tumor-Infiltrating Dendritic Cells: From In Situ Visualization to High-Dimensional Analyses
Hubert, M., Gobbini, É., Bendriss‐Vermare, N., Caux, C., & Valladeau‐Guilemond, J. (2019) · Cancers · doi:10.3390/cancers11081082 · Cited by 49
Benítez, J. C., Recondo, G., Rassy, E., & Mezquita, L. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03250-1 · Cited by 49
Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma
Hoffmann, F., Zarbl, R., Niebel, D., Sirokay, J. D., Fröhlich, A., Posch, C., Holderried, T. A. W., Brossart, P., Saavedra, G., Kuster, P., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00883-9 · Cited by 46
“An IFN-γ signature has been shown to be associated with response to immune checkpoint inhibitors [44, 45].”
BackgroundThe Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy
Ahmed, M. E., Falasiri, S. S. A., Hajiran, A. J., Chahoud, J., & Spiess, P. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103334 · Cited by 53
Bañobre, J. R., Díaz, A. M., Calvo, O. F., Núñez, N. F., Medina, A., Santomé, L., Lázaro-Quintela, M., Mateos-González, M., Cid, N. G., López‐López, R., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100090 · Cited by 50
Bao, R., Spranger, S., Hernandez, K. M., Zha, Y., Pytel, P., Luke, J. J., Gajewski, T. F., Volchenboum, S. L., Cohn, S. L., & Desai, A. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002417 · Cited by 49
Klümper, N., Ralser, D. J., Zarbl, R., Schlack, K., Schrader, A. J., Rehlinghaus, M., Hoffmann, M. J., Niegisch, G., Uhlig, A., Trojan, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002949 · Cited by 47
Liu, Z., Weng, S., Xu, H., Wang, L., Liu, L., Zhang, Y., Guo, C., Dang, Q., Xing, Z., Lu, T., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.757919 · Cited by 55
“TIS is composed of 18 inflammatory genes associated with antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance (28).”
BackgroundBertucci, F., Niziers, V., de Nonneville, A. T., Finetti, P., Mescam, L., Mir, O., Italiano, A., Cesne, A. L., Blay, J., Ceccarelli, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003687 · Cited by 44
Hallett, R. M., Bonfill‐Teixidor, E., Iurlaro, R., Arias, A., Raman, S., Bayliss, P. E., Egorova, O., Neva-Alejo, A., McGray, A. R., Lau, E., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1888 · Cited by 45
Wang, X., Bai, H., Zhang, J., Wang, Z., Duan, J., Cai, H., Cao, Z., Lin, Q., Ding, X., Sun, Y., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.276 · Cited by 50
Noviello, T., Giacomo, A. M. D., Caruso, F. P., Covre, A., Mortarini, R., Scala, G., Costa, M. C., Coral, S., Fridman, W. H., Sautès‐Fridman, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40994-4 · Cited by 50
Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility
Leonard‐Murali, S., Bhaskarla, C., Yadav, G. S., Maurya, S. K., Galiveti, C. R., Tobin, J. A., Kann, R. J., Ashwat, E., Murphy, P. S., Chakka, A. B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46906-4 · Cited by 50
Yin, X., Song, X., Deng, W., BLAKE, N. W., Luo, X., & Meng, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1483454 · Cited by 50
Choi, B., Lee, J. S., Kim, S. J., Hong, D., Park, J. B., & Lee, K.-Y. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.042 · Cited by 44
Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer
Nakayama, Y., Mimura, K., Kua, L., Okayama, H., Min, A. K. T., Saito, K., Hanayama, H., Watanabe, Y., Saito, M., Momma, T., et al. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01079-z · Cited by 46
Jiang, Q., Ghafoor, A., Mian, I., Rathkey, D., Thomas, A., Alewine, C., Sengupta, M., Ahlman, M. A., Zhang, J., Morrow, B., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz7252 · Cited by 47
Vollmer, T., Schlickeiser, S., Amini, L., Schulenberg, S., Wendering, D. J., Banday, V., Jurisch, A., Noster, R., Kunkel, D., Brindle, N. R., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb3735 · Cited by 45
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker
Fountzilas, E., Kurzrock, R., Vo, H. H., & Tsimberidou, A. M. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab067 · Cited by 50
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 45
Voorwerk, L., Isaeva, O. I., Horlings, H. M., Balduzzi, S., Chelushkin, M., Bakker, N. A. M., Champanhet, E., Garner, H., Sikorska, K., Loo, C. E., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00542-x · Cited by 44
Chen, D., Liu, P., Lu, X., Li, J., Qi, D., Zang, L., Lin, J., Liu, Y., Zhai, S., Fu, D., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03042-7 · Cited by 57
Tang, W., Wallace, T. A., Yi, M., Magi‐Galluzzi, C., Dorsey, T. H., Onabajo, O. O., Obajemu, A. A., Jordan, S. V., Loffredo, C. A., Stephens, R. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1060 · Cited by 45
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy
Rizk, E. M., Gartrell, R. D., Barker, L. W., Esancy, C. L., Finkel, G. G., Bordbar, D. D., & Saenger, Y. M. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.005 · Cited by 47
Labadie, B. W., Liu, P., Bao, R., Crist, M., Fernandes, R., Ferreira, L., Graupner, S., Poklepovic, A. S., Durán, I., Vareki, S. M., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02144-7 · Cited by 45
Alcaraz-Sanabria, A. L., Baliu‐Piqué, M., Sáiz-Ladera, C., Rojas, K., Manzano, A., Marquina, G., Casado, A., Cimas, F. J., Pérez‐Segura, P., Pandiella, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01486 · Cited by 45
Determinants of Resistance to Checkpoint Inhibitors
Tran, L. L., & Theodorescu, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051594 · Cited by 47
“Additionally, a T-cell-inflamed gene signature related to IFN-γ signaling is predictive of anti-PD-1 response across multiple cancers [64].”
BackgroundImpact of cancer evolution on immune surveillance and checkpoint inhibitor response
Wu, Y., Biswas, D., & Swanton, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.013 · Cited by 46
A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer
Liu, C., Gong, J., Yu, H., Liu, Q., Wang, S., & Wang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.544339 · Cited by 45
“Different biomarkers have been investigated to predict the efficacy and prognosis, such as PDL1 expression and copy number gains (1–4, 8–11), tumor mutation burden (TMB) (12–14), microsatellite instability (MSI) (15), tumor infiltrating lymphocytes (16–18) and inflammatory cytokines (19).”
BackgroundEngineered Cytokines for Cancer and Autoimmune Disease Immunotherapy
Uricoli, B., Birnbaum, L. A., Do, P., Kelvin, J., Jain, J., Costanza, E., Chyong, A., Porter, C. C., Rafiq, S., & Dreaden, E. C. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002214 · Cited by 46
Lee, M. Y., Robbins, Y. L., Sievers, C. M., Friedman, J., Sater, H. A., Clavijo, P. E., Judd, N. P., Tsong, E., Silvin, C., Soon‐Shiong, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002128 · Cited by 44
Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors
Wang, L., Londono, L. M., Cowell, J., Saatci, Ö., Aras, M., Ersan, P. G., Serra, S., Pei, H., Clift, R., Zhao, Q., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0340 · Cited by 46
Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine
Feng, F., Shen, B., Mou, X., Li, Y., & Li, H. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.03.007 · Cited by 55
Shi, D., Mu, S., Pu, F., Liu, J., Zhong, B., Hu, B., Ni, N., Wang, H., Luu, H. H., Haydon, R. C., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13160 · Cited by 48
Tan, A. R., Wright, G. S., Thummala, A. R., Danso, M. A., POPOVIC, L. S., Pluard, T., Han, H. S., Vojnović, Ž., Vasev, N., Ma, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2272 · Cited by 47
Wong, C. W., Evangelou, C., Sefton, K. N., Leshem, R., Zhang, W., Gopalan, V., Chattrakarn, S., Carro, M. L. F., Uzuner, E., Mole, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41737-1 · Cited by 48
Rapisuwon, S., Izar, B., Batenchuk, C., Avila, A., Mei, S., Sorger, P. K., Parks, J. M., Cooper, S. J., Wagner, D. H., Zeck, J. C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0533-0 · Cited by 44
Peskov, K. V., Azarov, I., Chu, L., Voronova, V., Kosinsky, Y., & Helmlinger, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00924 · Cited by 43
Lazarou, G., Chelliah, V., Small, B. G., Walker, M., van der Graaf, P. H., & Kierzek, A. M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1786 · Cited by 40
Huang, M., He, M., Guo, Y., Li, H., Shen, S., Xie, Y., Li, X., Xiao, H., Fang, L., Li, D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3840 · Cited by 42
The Abscopal Effect in the Era of Checkpoint Inhibitors
Kodet, O., Němejcová, K., Strnadová, K., Havlínová, A., Dundr, P., Krajsová, I., Štork, J., Smetana, K., & Lacina, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137204 · Cited by 42
Down-regulation of A20 promotes immune escape of lung adenocarcinomas
Breitenecker, K., Homolya, M., Luca, A. C., Lang, V., Trenk, C., Petroczi, G., Mohrherr, J., Horvath, J., Moritsch, S., Haas, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc3911 · Cited by 47
Melo, C. M., Vidotto, T., Chaves, L. P., Lautert-Dutra, W., dos Reis, R. B., & Squire, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179550 · Cited by 52
Insa, A., Martín-Martorell, P., Liello, R. D., Fasano, M., Martini, G., Napolitano, S., Vicidomini, G., Cappabianca, S., Franco, R., Morgillo, F., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103538 · Cited by 47
Integrated analysis reveals the molecular features of fibrosis in triple-negative breast cancer
Ding, J.-H., Xiao, Y., Zhao, S., Xu, Y., Xiao, Y.-L., Shao, Z., Jiang, Y., & Di, G. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.02.003 · Cited by 50
Carlisle, J. W., Jansen, C. S., Cardenas, M. A., Sobierajska, E., Reyes, A. M., Greenwald, R., del Balzo, L., Prokhnevska, N., Küçük, Ö., Carthon, B. C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004803 · Cited by 46
Intimate communications within the tumor microenvironment: stromal factors function as an orchestra
Cheng, B., Yu, Q., & Wang, W. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-022-00894-z · Cited by 50
Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives
Ao, Y.-Q., Gao, J., Wang, S., Jiang, J.-H., Deng, J., Wang, H., Xu, B., & Ding, J. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01772-4 · Cited by 50
Patkar, S., Chen, A., Basnet, A., Bixby, A., Rajendran, R., Chernet, R., Faso, S., Kumar, P. A., Desai, D., El-Zammar, O., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00765-w · Cited by 41
Zhu, X., Tian, X., Ji, L., Zhang, X., Cao, Y., Shen, C., Hu, Y., Wong, J. W. H., Fang, J.-Y., Hong, J., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00142-x · Cited by 41
Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
Yiong, C. S., Lin, T. P., Lim, V., Toh, T. B., & Yang, V. S. (2023) · Biomarker Research · doi:10.1186/s40364-023-00513-5 · Cited by 46
Freyer, G., Floquet, A., Trédan, O., Carrot, A., Langlois‐Jacques, C., Lopez, J., Selle, F., Abdeddaim, C., Leary, A. F., Dubot, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45974-w · Cited by 47
Hu, H., Tong, K., Tsang, J. Y., Ko, C. W., Tam, F., Loong, T., & Tse, G. M.-K. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102993 · Cited by 48
Ayers, M., Nebozhyn, M., Cristescu, R., McClanahan, T. K., Perini, R. F., Rubin, E. H., Cheng, J. D., Kaufman, D. R., & Loboda, A. P. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1316 · Cited by 43
Self-citationIdentification of risk in cutaneous melanoma patients: Prognostic and predictive markers
Hyams, D. M., Cook, R. W., & Buzaid, A. C. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25319 · Cited by 44
Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer
Zhang, F., Bai, H., Gao, R., Fei, K., Duan, J., Zhang, Z., Wang, J., & Hu, X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02642-4 · Cited by 44
Hyperprogression: A novel response pattern under immunotherapy
Han, X., Alu, A., Xiao, Y., Wei, Y., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.167 · Cited by 42
Guan, X., Wang, Y., Sun, Y., Zhang, C., Ma, S., Zhang, D., Li, D., & Jia, W. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s341981 · Cited by 46
Jin, K., Yu, Y., Zeng, H., Liu, Z., You, R., Zhang, H., Liu, C., Su, X., Yan, S. R., Chang, Y., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01725-6 · Cited by 44
Zhao, X., Cohen, E. E. W., William, W. N., Bianchi, J. J., Abraham, J. P., Magee, D., Spetzler, D. B., Gutkind, J. S., Alexandrov, L. B., Cavenee, W. K., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2213835119 · Cited by 50
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
Davar, D., & Zarour, H. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1129 · Cited by 40
Zhang, H., Wang, Z., Dai, Z., Wu, W., Cao, H., Li, S., Zhang, N., & Cheng, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694490 · Cited by 52
“Scatter plots depicting a positive correlation between ICP score and (F) CYT and (H) GEP.”
BackgroundInfluentialPhillips, C., Bhamra, I., Eagle, C., Flanagan, E., Armer, R., Jones, C. D., Bingham, M., Calcraft, P., Edmenson Cook, A., Thompson, B., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0095 · Cited by 36
Alburquerque-Béjar, J. J., Navajas-Chocarro, P., Saigí, M., Ferrero-Andres, A., Morillas, J. M., Vilarrubi, A., Gómez, A., Mate, J. L., Muñoz-Mármol, A. M., Romero, O. A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101006 · Cited by 57
Frijlink, E., Bosma, D. M. T., Busselaar, J., Battaglia, T., Staal, M. D., Verbrugge, I., & Borst, J. G. (2024) · Journal of Clinical Investigation · doi:10.1172/jci171154 · Cited by 46
de Lange, M. J., Nell, R. J., Lalai, R. N., Versluis, M., Jordanova, E. S., Luyten, G. P. M., Jager, M. J., van der Burg, S. H., Zoutman, W. H., van Hall, T., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0114 · Cited by 42
Saigí, M., Alburquerque-Béjar, J. J., & Sánchez‐Céspedes, M. (2019) · Oncogene · doi:10.1038/s41388-019-0855-x · Cited by 41
Manasanch, E. E., Han, G., Mathur, R., Qing, Y., Zhang, Z., Lee, H. C., Weber, D. M., Amini, B., Berkova, Z., Eterovic, K. A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000300 · Cited by 40
Miyahira, A. K., Sharp, A., Ellis, L., Jones, J. C., Kaochar, S., Larman, H. B., Quigley, D. A., Ye, H., Simons, J. W., Pienta, K. J., et al. (2019) · The Prostate · doi:10.1002/pros.23934 · Cited by 42
Zhang, S., Bai, X., & Shan, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106247 · Cited by 43
CD8+ T-cell–Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas
KANE, J. R., Zhao, J., Tsujiuchi, T., Laffleur, B., Mahajan, A., Rao, G., Mela, A., Dmello, C., Arrieta, V. A., Chen, L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3104 · Cited by 45
Larocca, C. A., LeBoeuf, N. R., Silk, A. W., & Kaufman, H. L. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00554-8 · Cited by 46
Song, Y., Huang, J., Liang, D., Hu, Y., Mao, B., Li, Q., Sun, H., Yang, Y., Zhang, J., Zhang, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.549777 · Cited by 37
“Immune Gene Signatures The gene sets for cytolytic activity, IFN g signature, immunocostimulators, immunoinhibitors, chemokines, T cell– inflamed gene expression profile (GEP), and MHC-class-I/II signature were defined in previous reports (25, 26).”
BackgroundImmune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma
Veigas, F., Mahmoud, Y. D., Merlo, J. P., Rinflerch, A., Rabinovich, G. A., & Girotti, M. R. (2021) · Cancers · doi:10.3390/cancers13051018 · Cited by 45
Sun, Y., Jing, J., Xu, H., Xu, L., Hu, H., Tang, C., Liu, S., Wei, Q., Duan, R., Guo, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002138 · Cited by 41
Xia, L., Guo, L., Kang, J. U., Yang, Y., Yao, Y., Xia, W., Sun, R., Zhang, S., Li, W., Gao, Y.-E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.759217 · Cited by 43
“In addition, a high tumor mutation burden (2, 3), intratumor immunological signatures (4, 5), as well as increased diversity of gut microbiota (6, 7) are also reported to be associated with better responses to ICI treatment.”
BackgroundFreeman, S. S., Sade-Feldman, M., Kim, J., Stewart, C., Gonye, A. L. K., Ravi, A., Arniella, M. B., Gushterova, I., LaSalle, T. J., Blaum, E. M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100500 · Cited by 41
Metadata
- Authors
- Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., Piha-Paul, S. A., Yearley, J., Seiwert, T. Y., Ribas, A., & McClanahan, T. K.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Washington (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Chicago (US)
- University of California, Los Angeles (US)
- Corresponding author
- McClanahan, Terrill K.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-06-26
- Volume
- 127
- Issue
- 8
- Pages
- 2930-2940
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5531419
- OpenAlex
- W2655262992
- Cited by
- 3,788
- References
- 31
- Citations by year
- 2026: 358 · 2025: 391 · 2024: 518 · 2023: 551 · 2022: 608 · 2021: 512 · 2020: 400 · 2019: 263 · 2018: 159 · 2017: 24
- FWCI
- 101.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- interferon-gamma, anti-PD-1 therapy, pembrolizumab, predictive biomarkers, gene expression profiles, PD-L1 expression, immune checkpoint inhibitors, melanoma, head and neck squamous cell carcinoma, adaptive immune resistance, antigen presentation, chemokine expression
- MeSH terms
- Antineoplastic Agents, Biopsy, Carcinoma, Carcinoma, Non-Small-Cell Lung, Humans, Immune System, Immunohistochemistry, Interferon-gamma, Lung Neoplasms, Melanoma, Pilot Projects, ROC Curve, Skin Neoplasms, Stomach Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Treatment Outcome, Sequence Analysis, RNA, Gene Expression Profiling, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.